HSIC

Henry Schein (HSIC) possesses solid growth attributes, which could help it handily outperform the market.

Henry Schein (HSIC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Investors with an interest in Medical - Dental Supplies stocks have likely encountered both Henry Schein (HSIC) and Merit Medical (MMSI). But which of these two stocks presents investors with the better value opportunity right now?

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Henry Schein, Inc. ( HSIC ) Q3 2026 Earnings Call November 3, 2026 8:00 AM EST Company Participants Graham Stanley - VP of Investor Relations & Strategic Finance Project Officer Frederick Lowery - CEO & Director Emmanuel Caprais Ronald South - Senior VP & CFO Conference Call Participants Elizabeth Anderson - Evercore ISI Institutional Equities, Research Division Jeffrey Johnson - Robert W. Baird & Co. Incorporated, Research Division Jason Bednar - Piper Sandler & Co., Research Division Jonathan Block - Stifel, Nicolaus & Company, Incorporated, Research Division Erin Wilson Wright - Morgan Stanley, Research Division Allen Lutz - BofA Securities, Research Division John Stansel - JPMorgan Chase & Co, Research Division Kevin Caliendo - UBS Investment Bank, Research Division Michael Cherny - Leerink Partners LLC, Research Division Brandon Vazquez - William Blair & Company L.L.C.

Henry Schein NASDAQ: HSIC reported third-quarter results marked by higher U.S. dental merchandise sales, margin expansion and improved underlying earnings, while raising its full-year non-GAAP earnings outlook.

While the top- and bottom-line numbers for Henry Schein (HSIC) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Henry Schein beats Q3 earnings estimates, matches revenue forecasts and raises its 2026 EPS outlook, yet shares slip despite strong dental and technology sales.